文献速递泌尿系感染男科与性医学

新型P100体外冲击波治疗IIIB型慢性前列腺炎/慢性盆腔疼痛综合征的疗效:一项假治疗对照前瞻性临床试验

Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-01-28

该随机单盲假治疗对照试验纳入83例IIIB型CP/CPPS患者,P100组51例接受每周一次低强度ESWT(0.2 mJ/mm²)共4次,对照组32例接受阻断冲击传输的相同操作。第4周临床应答率P100组78.4%显著高于对照组25%(P<0.001),NIH-CPSI中位数从基线35降至第4周13、第8周12,症状缓解持续且无反弹,未报告治疗相关不良事件。

要点

  • P100 ESWT第4周临床应答率78.4%,显著高于假治疗组25%(P<0.001)。
  • NIH-CPSI中位数由基线35降至第4周13、第8周12,改善持续无反弹。
  • PDS、IPSS、VAS评分最早第2周显著下降(P<0.05),未见治疗相关不良事件。

核心结论

  • P100 ESWT对IIIB型CP/CPPS提供快速、显著且持续的症状缓解,尤其在疼痛和排尿领域。
  • 激素平衡(E2/T)可能影响ESWT后勃起功能的长期维持。
  • P100可作为CP/CPPS安全有效的非侵入性治疗选择,但需更大样本和更长随访进一步验证。

研究设计与样本

  • 随机、单盲、假治疗对照前瞻性临床试验,纳入83例IIIB型CP/CPPS患者。
  • P100治疗组51例,接受每周一次低强度ESWT(0.2 mJ/mm²)共4次;对照组32例接受冲击传输阻断的相同操作。
  • 主要终点为第4周临床应答率(NIH-CPSI评分降低≥6分),第8周进一步分析持续疗效。
  • 次要终点包括IPSS、IIEF-5和VAS评分。

主要发现

  • 第4周临床应答率P100组78.4%,对照组25%(P<0.001)。
  • NIH-CPSI中位数从基线35降至第4周13和第8周12,提示持续改善。
  • PDS、IPSS和VAS评分最早第2周显著下降(P<0.05),症状缓解稳定至第8周无反弹。
  • 探索性分析提示较低基线雌二醇水平和较低E2/T比值可能与勃起功能更持续改善相关。
  • 未报告治疗相关不良事件。

关键数值与推荐

  • 临床应答定义为NIH-CPSI评分降低≥6分。
  • ESWT方案为每周一次低强度0.2 mJ/mm²,共4次。

临床怎么用

  • P100 ESWT可作为IIIB型CP/CPPS的非侵入性治疗选项,重点关注疼痛和排尿症状改善。
  • 治疗前可关注雌二醇水平和E2/T比值,或有助于预判勃起功能长期维持效果。

局限性

  • 样本量有限(共83例),需更大样本研究验证。
  • 随访至第8周,需更长随访评估长期疗效。
  • 探索性激素分析结果需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the therapeutic efficacy and clinical applicability of the novel P100 extracorporeal shock wave therapy (ESWT) device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). METHODS: In this randomized, single-blind, sham-controlled trial, 83 patients with type IIIB CP/CPPS were enrolled and randomly assigned to either the P100 treatment group (n = 51) or the control group (n = 32). Patients in the treatment group received four weekly low-intensity ESWT sessions (0.2 mJ/mm²), while the control group received identical procedures with shock transmission blocked. The primary endpoint was the clinical response rate (≥6-point reduction in NIH-CPSI score) at week 4; week 8 outcomes were further analyzed to assess sustained efficacy. Secondary endpoints included IPSS, IIEF-5, and VAS scores. RESULTS: At week 4, the clinical response rate was 78.4% in the P100 group compared with 25% in the control group (P < 0.001). Median NIH-CPSI scores decreased from 35 at baseline to 13 at week 4 and 12 at week 8, indicating sustained improvement. Significant reductions in PDS, IPSS, and VAS scores were observed as early as week 2 (P < 0.05), and symptom relief remained stable through week 8 without rebound. Exploratory analyses suggest that lower baseline estradiol levels and lower E2/T ratios may be associated with more sustained improvements in erectile function. No treatment-related adverse events were reported. CONCLUSION: The P100 ESWT device provided rapid, significant, and sustained symptom relief for type IIIB CP/CPPS, particularly in pain and urinary domains. Hormonal balance (E2/T) may influence the long-term maintenance of erectile function after ESWT. These findings support P100 as a safe and effective non-invasive therapeutic option for CP/CPPS, warranting further validation in larger studies with longer-term follow-up.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Zhang H, Song W, Ni J, et al. Efficacy of the new P100 extracorporeal shock wave therapy device in the treatment of type IIIB chronic prostatitis/chronic pelvic pain syndrome: a sham treatment controlled, prospective clinical trial. Prostate Cancer Prostatic Dis. 2026. PMID: 41593221. doi:10.1038/s41391-026-01072-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。